Main Street Research LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 9.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,427 shares of the company’s stock after selling 1,534 shares during the period. Johnson & Johnson accounts for 0.5% of Main Street Research LLC’s holdings, making the stock its 29th largest position. Main Street Research LLC’s holdings in Johnson & Johnson were worth $2,391,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the stock. LCM Capital Management Inc increased its position in shares of Johnson & Johnson by 0.7% during the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after buying an additional 61 shares during the period. Arbor Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the period. Sierra Capital LLC boosted its position in shares of Johnson & Johnson by 0.6% during the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares in the last quarter. Lockerman Financial Group Inc. increased its holdings in Johnson & Johnson by 2.4% in the fourth quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock worth $474,000 after purchasing an additional 62 shares in the last quarter. Finally, OneAscent Financial Services LLC lifted its stake in Johnson & Johnson by 3.3% in the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock valued at $308,000 after buying an additional 63 shares during the period. Institutional investors and hedge funds own 67.57% of the company’s stock.
Johnson & Johnson Trading Up 0.6 %
NYSE JNJ opened at $173.71 on Friday. The stock has a market capitalization of $451.43 billion, a price-to-earnings ratio of 35.16, a PEG ratio of 2.89 and a beta of 0.55. The business’s fifty day moving average is $161.14 and its 200-day moving average is $161.22. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.74%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is owned by insiders.
Analyst Ratings Changes
Several brokerages have recently commented on JNJ. Stifel Nicolaus raised their target price on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Raymond James upped their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a report on Monday. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Finally, Barclays raised their price target on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research report on Monday. Eight investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Hold” and an average target price of $171.60.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Want to Profit on the Downtrend? Downtrends, Explained.
- Is AI On The Verge Of A Monster Short Squeeze Breakout?
- How to Invest in Blue Chip Stocks
- Chipotle Mexican Grill Serves Up Another Entry PointÂ
- Mega Cap Stocks: What They Are and How to Invest
- 7 Best Hotel REITs to Buy Now
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
